Corona Remedies Limited

As of March 31, 2026, Corona Remedies Limited carries a market capitalization of 95.17B, placing it among publicly traded companies globally. Its enterprise value stands at 96.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Corona Remedies Limited's next confirmed earnings release is scheduled for December 2, 2026.

As of March 31, 2026, Corona Remedies Limited has 61.16M shares outstanding.

As of March 31, 2026, Corona Remedies Limited trades at a trailing price-to-earnings ratio of 57.91. The price-to-sales ratio is 7.13, and the price-to-book ratio stands at 12.74.

As of March 31, 2026, Corona Remedies Limited trades at an EV/EBITDA multiple of 38.54 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.22 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 45.59 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 96.38B versus a market cap of 95.17B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Corona Remedies Limited maintains a current ratio of 0.96, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.07, indicating elevated leverage, while an interest coverage ratio of 37.72 demonstrates strong ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2026. The company generates approximately 2.98M in revenue per employee across its workforce of 4,479.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended March 31, 2026, Corona Remedies Limited recorded 499.07M in income tax expense. That works out to an effective tax rate of 23.29, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.14B, leaving 1.64B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 2,100.03, while the 200-day moving average is 1,800.53.

Over the twelve months ended March 31, 2026, Corona Remedies Limited generated 13.35B in revenue and converted that into 1.64B in net income, yielding earnings per share of 26.87. EBITDA reached 2.50B, while operating income came in at 2.31B.

As of March 31, 2026, Corona Remedies Limited holds 444.20M in cash and equivalents against 1.65B in total debt, resulting in a net debt position of 1.41B. Total book value stands at 7.47B, with working capital of -128.60M providing operational flexibility.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Corona Remedies Limited posted a gross margin of 81.34, reflecting its pricing power and cost economics. The operating margin of 17.27 and net profit margin of 12.31 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Corona Remedies Limited paid dividends of 6.67 per share. The dividend payout ratio of 24.84 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

As of March 31, 2026, Corona Remedies Limited has an Altman Z-Score of 15.63, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.